BioNexus Gene Lab (BGLC) director files Form 3 with zero shares
Rhea-AI Filing Summary
BioNexus Gene Lab Corp reports initial insider holdings for director Yap Chee Keong. The disclosure lists a holding entry for common stock with 0.0000 shares owned directly as of the reported date, indicating no reportable direct equity position in the company’s common stock at that time.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Yap Chee Keong
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | COMMON STOCK | -- | -- | -- |
Holdings After Transaction:
COMMON STOCK — 0 shares (Direct)
Key Figures
Common stock held directly: 0.0000 shares
Reported buy shares: 0 shares
Reported sell shares: 0 shares
3 metrics
Common stock held directly
0.0000 shares
Total BioNexus Gene Lab common shares beneficially owned directly by Yap Chee Keong following the holding entry
Reported buy shares
0 shares
Total shares classified as purchases in the transaction summary for this Form 3
Reported sell shares
0 shares
Total shares classified as sales in the transaction summary for this Form 3
Key Terms
COMMON STOCK, direct_or_indirect, derivativeSummary
3 terms
COMMON STOCK financial
"security_title: "COMMON STOCK" for the reported holding entry"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
direct_or_indirect regulatory
""direct_or_indirect": "D" indicates direct ownership type"
derivativeSummary financial
""derivativeSummary": [] lists derivative positions, if any"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does BioNexus Gene Lab (BGLC) director Yap Chee Keong report on this Form 3?
The Form 3 shows director Yap Chee Keong directly owns 0.0000 shares of BioNexus Gene Lab common stock. It reports a single holding entry for common stock and no beneficially owned shares following that entry, indicating no direct equity position at the reported time.
Does BioNexus Gene Lab (BGLC) director Yap Chee Keong report any insider transactions in this Form 3?
The disclosure lists a holding entry with 0.0000 common shares and no transaction share amount or price. It functions as an initial statement of holdings, without reporting any specific purchase or sale quantities of BioNexus Gene Lab common stock in this record.
Is Yap Chee Keong identified as a director or officer of BioNexus Gene Lab (BGLC) in this Form 3?
He is identified as a director of BioNexus Gene Lab Corp and not as an officer. The reporting-person information flags his director status while indicating no officer role or title, tying the zero-share holding disclosure to his position on the company’s board.
Does the BioNexus Gene Lab (BGLC) Form 3 show any derivative securities for Yap Chee Keong?
The available data show no listed derivative securities for Yap Chee Keong in this Form 3. The derivative section is empty, and only a single holding entry for common stock is present, with total direct common stock ownership reported as 0.0000 shares.